Skip to main content
. Author manuscript; available in PMC: 2020 Dec 15.
Published in final edited form as: Adv Drug Deliv Rev. 2020 Apr 28;159:232–244. doi: 10.1016/j.addr.2020.04.009

Fig. 3.

Fig. 3.

Brain regional sphingolipid metabolism impairment in psychiatric disorders. Summary from various studies of alterations observed in sphingolipid metabolism at the brain regional level in human post-mortem psychiatric patients or rodent models of psychiatric diseases such as exposure to chronic stress or to substances of abuse associated with addiction. SM, sphingomyelin; Cer, ceramide; GalCer, galactosylceramide; LacCer, lactosylceramide.